7EQV
Crystal structure of JMJD2A complexed with 3,4-dihydroxybenzoic acid
Summary for 7EQV
| Entry DOI | 10.2210/pdb7eqv/pdb |
| Descriptor | Lysine-specific demethylase 4A, 3,4-DIHYDROXYBENZOIC ACID, NICKEL (II) ION, ... (6 entities in total) |
| Functional Keywords | human histone lysine demethylase 4a, lysine-specific demethylase 4a, kdm4a, jmjd2a, 3, 4-dihydroxybenzoic acid, inhibitor, oxidoreductase |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 1 |
| Total formula weight | 40887.01 |
| Authors | Fang, W.-K.,Yang, S.-M.,Wang, W.-C. (deposition date: 2021-05-04, release date: 2022-05-18, Last modification date: 2023-11-29) |
| Primary citation | Liu, J.S.,Fang, W.K.,Yang, S.M.,Wu, M.C.,Chen, T.J.,Chen, C.M.,Lin, T.Y.,Liu, K.L.,Wu, C.M.,Chen, Y.C.,Chuu, C.P.,Wang, L.Y.,Hsieh, H.P.,Kung, H.J.,Wang, W.C. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer. J.Biomed.Sci., 29:29-29, 2022 Cited by PubMed Abstract: Castration-resistant prostate cancer (CRPC) with sustained androgen receptor (AR) signaling remains a critical clinical challenge, despite androgen depletion therapy. The Jumonji C-containing histone lysine demethylase family 4 (KDM4) members, KDM4A‒KDM4C, serve as critical coactivators of AR to promote tumor growth in prostate cancer and are candidate therapeutic targets to overcome AR mutations/alterations-mediated resistance in CRPC. PubMed: 35534851DOI: 10.1186/s12929-022-00812-3 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.6 Å) |
Structure validation
Download full validation report
